NASDAQ:NPCE

H.C. Wainwright Raises Price Target for NeuroPace (NASDAQ: NPCE) Amid Strong Q1 Performance

Font: Financial Modeling Prep  • May 15, 2026

Market Chart
  • Analyst firm H.C. Wainwright raised its price target for NeuroPace to $20.00, indicating a potential 32.54% upside.
  • NeuroPace (NASDAQ: NPCE) reported strong Q1 2026 financial performance with total revenues of $22.1 million and an improved adjusted loss of $0.13 per share.
  • Growth was significantly driven by the company's RNS System, with sales increasing 19.5% year-over-year, leading to raised 2026 revenue guidance.

Analyst firm H.C. Wainwright raises its price target for NeuroPace to $20.00. This new target represents a potential 32.54% upside from its trading price of $15.09 at the time. NeuroPace is a medical device company that develops and markets a system to treat neurological disorders, such as epilepsy.

The positive analyst outlook follows a strong first-quarter 2026 performance. As highlighted by Zacks, NeuroPace reports total revenues of $22.1 million and a smaller adjusted loss of $0.13 per share. This is an improvement from the $0.18 per share loss in the same period last year, showing better financial control.

A key driver for this growth is the company's RNS System. Sales for this system grew 19.5% year-over-year, reaching $21.7 million. This strong demand is a primary reason for the company's success. Management notes all-time highs in active prescribers and its patient pipeline, which signal sustained future demand.

Due to these results, NeuroPace raises its revenue guidance for 2026. The company now expects its RNS System revenue to grow between 21% and 23% for the full year. This updated forecast reflects management's confidence in its commercial execution and the continued adoption of its technology in the market.

While the company reports a GAAP net loss of $6.7 million, its adjusted EBITDA loss improves to $3.3 million from $4.1 million a year prior. Adjusted EBITDA provides a view of operational performance by excluding items like interest and taxes. This improvement suggests the core business is becoming more efficient.

Market Overview
VRAX
Virax Biolabs Group Limited
$0.24
53.09%
WGRX
Wellgistics Health, Inc.
$0.17
108.38%
AIM
AIM ImmunoTech Inc.
$0.41
61.26%
SBFM
Sunshine Biopharma, Inc.
$0.51
79.51%
SOXS
Direxion Daily Semiconductor Bear 3X ETF
$9.95
7.80%
TZA
Direxion Daily Small Cap Bear 3X ETF
$5.05
1.81%
PMI
Picard Medical, Inc.
$0.17
7.06%
GOVX
GeoVax Labs, Inc.
$2.21
79.67%
NXXT
NextNRG Inc.
$0.41
46.22%
CREG
Smart Powerr Corp.
$0.62
30.59%